You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

383 Results
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Adjuvant
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    osimertinib - For the treatment of locally advanced (not amenable to curative therapies) or metastatic non-small cell lung cancer (NSCLC) according to clinical criteria
Dec 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Mar 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
Apr 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Intent: Palliative
Jul 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Nov 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023

Pages